Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutica...(g the previous fiscal year nine-mon...)

Date:5/19/2009

g the previous fiscal year nine-month period ended February 29, 2008. Profitability Growth: --------------------- - Consolidated EBITDA for the nine-month period ended February 28, 2009 represents $337,000 compared to $750,000 obtained during the nine-month period ended February 29, 2008. - EBITDA for Neptune Nutraceutical, excluding Acasti Pharma et NeuroBioPharm, for the nine-month period ended February 28, 2009 amounted to $1,238,000 which represents an increase of 65% compared to the nine-month period ended February 29, 3008. Earnings Growth: ---------------- - Net loss decreased by $1,611,000 and represents $1,889,000 or $0.05 per share which is an improvement of 46% for the nine-month period ended February 28, 2009 compared to a net loss of $3,500,000 or $0.095 per share, for the previous fiscal nine-month period. This improvement is mainly due to an increase in productivity as well as an increase of gross margins reflected in the costs of sales and operating expenses. Cash Position ------------- - The Company believes that Neptune's cash position and financial performance provide for a self-sustainable profitable nutraceutical business. As of February 28, 2009, Neptune's cash and cash equivalents totalled $4,154,000. Neptune announces amendments to the Company and the Acasti stock options plans Neptune announces that on April 29, 2009, its subsidiary Acasti Pharma amended the existing stock option plan for directors, officers, employees and consultants initially adopted on October 8, 2008 (the "Acasti Plan"), as required by the TSX Venture Exchange. The Acasti Plan now allows the board of directors of Acasti to grant options for Acasti Class A shares representing up to 10% of the outstanding issued Acasti shares subject to a maximum of 1,530,000 Acasti options. On April 29, 20
'/>"/>

SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Neptune Product and Distribution Update
2. Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results
3. Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinetic profile
4. Acasti Pharma completes offer to exchange outstanding Neptune Technologies dividend notes
5. Neptune Technologies & Bioressources Inc. reports first quarter results
6. Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
7. Neptune Technologies and Marine Life Sciences enter worldwide distribution alliance with Weider Global Nutrition
8. Neptune Krill Oil, NKO(R), enters WALGREENS, the largest U.S. retail pharmacy chain, under the brand name Schiff(R) MegaRed(TM)
9. Neptune Technologies decided not to re-price options
10. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
11. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results